How Are Peptides Made? 6-Step Solid-Phase Synthesis Guide

Every peptide in every vial — whether it is BPC-157, semaglutide, or any of the 44 compounds profiled on Peptigrity — is manufactured through the same fundamental process: solid-phase peptide synthesis (SPPS), a method invented in 1963 by Robert Bruce Merrifield that builds amino acid chains one residue at a time on a solid resin support, then purifies and freeze-dries the result into the lyophilised powder buyers receive.

The quality of the final product depends directly on the precision of each synthesis step. Even at 99.5% coupling efficiency per amino acid — considered excellent — a 30-residue peptide retains only about 86% correct full-length chains, with the remaining 14% consisting of truncated sequences, deletion peptides, and side-reaction products that must be removed by HPLC purification. Understanding how peptides are made explains why peptide purity standards exist, why impurities are an inherent feature of chemical synthesis, and why the price difference between vendors for the "same" peptide often reflects real quality differences in purification rigour.

What Is Solid-Phase Peptide Synthesis (SPPS)?

Solid-phase peptide synthesis (SPPS) is the process of building a peptide chain one amino acid at a time on an insoluble resin bead — a method invented by Robert Bruce Merrifield in 1963 that earned him the Nobel Prize in Chemistry in 1984 and remains the foundation of virtually all peptide manufacturing over 60 years later.

The core innovation is elegantly simple. By anchoring the growing peptide chain to an insoluble solid support (typically polystyrene cross-linked with divinylbenzene), excess reagents and byproducts from each reaction step can be washed away by simple filtration. There is no need for complex chromatographic purification between each amino acid addition — the peptide stays on the bead while everything else is rinsed away. This made the synthesis of peptides longer than 10 amino acids practical for the first time.

Before SPPS, peptides were assembled in solution — a process requiring laborious purification after every single coupling step. Solution-phase synthesis was effective for very short peptides (2–5 amino acids) but became impractical as chain length increased. SPPS removed this bottleneck, enabling routine synthesis of peptides up to approximately 50 amino acids and, with difficulty, up to 100 amino acids. For even larger targets, shorter fragments are synthesised separately by SPPS and then joined using techniques such as native chemical ligation.

SPPS is also highly automatable. Modern peptide synthesisers perform the repetitive deprotection-coupling-wash cycles without manual intervention, running overnight to complete sequences that would take weeks by hand. This automation is fundamental to the peptide industry's ability to supply compounds at the milligram-to-kilogram scale.

One detail that surprises many: SPPS builds peptides from the C-terminus to the N-terminus — the reverse of how ribosomes build proteins in biological systems (N to C). This direction was chosen because the coupling chemistry produces fewer side reactions (particularly less racemisation) when the incoming amino acid is activated at its C-terminal carboxyl group and coupled to the free N-terminal amine of the growing chain.

The 6 Steps of SPPS — How a Peptide Is Built From Scratch

Every synthetic peptide — from a 4-amino-acid epitalon to a 31-amino-acid semaglutide — is manufactured through the same 6-step cycle: attach the first amino acid to a resin, remove the protecting group, couple the next amino acid, repeat until the sequence is complete, cleave the finished chain from the resin, then purify and freeze-dry the result.

Step 1: Attach the First Amino Acid to the Resin

The C-terminal amino acid of the target peptide is chemically linked to the solid resin bead through a "linker" molecule. The amino acid's N-terminal amine is protected with a temporary protecting group — either Fmoc (9-fluorenylmethoxycarbonyl) in modern synthesis or Boc (tert-butyloxycarbonyl) in the original method. Any reactive side-chain groups are also protected with permanent groups that remain in place throughout chain assembly and are removed only during the final cleavage step.

Step 2: Remove the Temporary Protecting Group (Deprotection)

The temporary N-terminal protecting group is removed to expose the free amine. In Fmoc chemistry — the modern standard — this uses 20% piperidine in DMF, a mild base that cleaves the Fmoc group while leaving acid-labile side-chain protections intact. The released Fmoc group produces a UV-absorbing chromophore detectable at 301 nm, giving automated synthesisers a real-time measure of deprotection efficiency. The resin is washed thoroughly after deprotection.

Step 3: Activate and Couple the Next Amino Acid

The next protected amino acid is activated using a coupling reagent — commonly HATU, HBTU, or DIC/HOBt — converting its carboxyl group into a reactive form. The activated amino acid reacts with the exposed N-terminal amine on the resin-bound chain, forming a new peptide bond and extending the chain by one residue. Coupling efficiency must exceed 99% per residue to maintain acceptable final purity, as described in the comprehensive review "Introduction to Peptide Synthesis". The resin is washed again after coupling.

Step 4: Repeat the Cycle

Steps 2 and 3 repeat for each amino acid in the target sequence. For BPC-157 (15 amino acids): 14 cycles. For CJC-1295 without DAC (29 amino acids): 28 cycles. For semaglutide (31 amino acids plus lipidation): 30+ cycles plus post-synthesis modification. Each cycle takes approximately 30–90 minutes. Total synthesis time: hours for short peptides, days for longer or difficult sequences.

Step 5: Cleavage and Global Deprotection

The completed peptide is cleaved from the resin and all side-chain protecting groups are removed simultaneously using a TFA cocktail (TFA with scavengers such as triisopropylsilane, water, and ethanedithiol) for 2–4 hours. The result is a "crude peptide" — the target peptide plus all synthesis byproducts. Crude purity is typically 60–85% depending on sequence length and difficulty, as noted in Bachem's pharmaceutical SPPS guide.

Step 6: Purification, Quality Control, and Lyophilisation

Reversed-phase HPLC separates the target peptide from impurities based on hydrophobicity. Analytical HPLC confirms final purity — typically ≥95% or ≥98% for research-grade products. Mass spectrometry (ESI-MS or MALDI-TOF) confirms the molecular weight matches the target sequence. The purified peptide is lyophilised into a stable powder, aliquoted into vials, sealed, and labelled. For guidance on interpreting the analytical data that accompanies a finished product, Peptigrity's guide on how to read peptide lab test results covers both HPLC and MS in detail.

Fmoc vs Boc — Why the Chemistry Matters for Quality

Modern peptide manufacturing uses Fmoc chemistry for approximately 98% of all synthesis — an approach that employs milder reagents, produces cleaner products, and is easier to automate and monitor than the original Boc chemistry it replaced, as documented in the review "Advances in Fmoc Solid-Phase Peptide Synthesis" (Behrendt et al., Journal of Peptide Science, 2016).

The Fmoc/tBu strategy uses an "orthogonal" protection scheme: the temporary Fmoc group is removed by base (piperidine), while the permanent tBu-based side-chain groups are removed by acid (TFA) during final cleavage. Because these conditions are chemically independent, each set of protecting groups can be manipulated without disturbing the other.

The original Boc/Bzl strategy used "graduated acid lability" instead — the temporary Boc group was removed by moderate acid (TFA), and the permanent Bzl groups plus the resin linkage required strong acid (anhydrous HF) for final cleavage. The requirement for HF — one of the most corrosive laboratory reagents — limited batch size, required specialised equipment, and posed significant safety hazards.

The buyer-relevant takeaway: the Fmoc/tBu method produces cleaner crude products under milder conditions, enabling higher-quality final products after purification. When you see HPLC purity ≥98% on a Certificate of Analysis, the synthesis was almost certainly Fmoc-based.

Fmoc vs Boc Comparison:

What Goes Wrong? Why Every Synthetic Peptide Has Impurities

No peptide synthesis achieves 100% coupling efficiency at every step — even at 99.5% efficiency per residue, a 30-amino-acid peptide yields only ~86% correct full-length product (0.995³⁰ = 0.860), and the remaining 14% consists of truncated sequences, deletion peptides, and side-reaction products that must be removed by HPLC purification before the peptide reaches your vial.

At a more typical coupling efficiency of 99%, the same 30-residue peptide yields only ~74% correct product — meaning over a quarter of the crude material is not the target peptide.

The 5 Types of Synthesis Impurities

1. Truncated sequences — The chain stopped growing because a coupling step failed completely. Capping — acetylating unreacted amines after each coupling — prevents truncated chains from continuing as deletion peptides, converting them into easily separable short fragments.

2. Deletion peptides — One or more amino acids were skipped because coupling was incomplete and the unreacted amine was not capped. The chain continued growing with a gap in the sequence. Deletion peptides are the most problematic impurity because their hydrophobicity and charge are very similar to the target, making them extremely difficult to separate by HPLC.

3. Side-reaction products — Chemical modifications during synthesis: racemisation (particularly at histidine and cysteine), aspartimide formation (at Asp-Gly sequences), and oxidation of methionine, tryptophan, and cysteine during cleavage.

4. Incompletely deprotected variants — Side-chain protecting groups not fully removed during final cleavage. Detectable by mass spectrometry as additional mass.

5. Residual reagents — TFA salts, trace scavengers, and resin fragments remaining after workup.

These impurities, documented in the peptide impurities literature, are a direct consequence of the synthesis process. HPLC purity ≥98% means they have been reduced to below 2% of the total. Crude-quality peptides (no purification) may contain 15–40% impurities. When you see price differences between vendors for the "same" peptide, a significant portion of that difference is the cost of purification. The HPLC trace on the CoA reveals whether impurities have been properly removed. Peptigrity's independent lab tests verify vendor purity claims through third-party analytical testing.

GMP vs Research-Grade — What Determines Manufacturing Quality?

The difference between a $30 research-grade peptide and a $300 pharmaceutical-grade peptide is not always the molecule itself — it is the facility controls, documentation, and regulatory oversight applied during manufacturing, which is why independent analytical testing remains the most reliable way to verify what is actually in the vial regardless of what the label or price suggests.

Research-grade / RUO (Research Use Only): Synthesised in non-GMP facilities using standard Fmoc SPPS. Analytical QC (HPLC + MS) confirms identity and purity, but the manufacturing environment is not controlled to pharmaceutical standards. This is what most peptide vendor products are. Typical purity: ≥95–98% by HPLC.

GMP (Good Manufacturing Practice): Synthesised in validated, inspected facilities with documented SOPs, controlled environments, raw material traceability, formal batch records, and regulatory oversight. Required for any peptide intended for human therapeutic use. Products such as Ozempic, Mounjaro, and Wegovy are manufactured under GMP at multi-ton scale. Significantly more expensive — the cost reflects facility compliance, not different chemistry.

Compounding-grade: An intermediate tier produced by licensed 503A/503B compounding pharmacies under USP standards (chapters 797/795) but not full GMP. Subject to state pharmacy board and, for 503B facilities, FDA oversight under compounding regulations.

The buyer-relevant distinction: a research-grade BPC-157 at 98% HPLC purity may be analytically identical to a GMP-grade BPC-157 at 98% purity — the HPLC trace and MS data would look the same. The difference is in manufacturing documentation, traceability, and facility controls, not necessarily the molecular product. However, lower-tier vendors may claim 98% purity without adequate QC to confirm it. Peptigrity's how to verify peptide quality before you buy framework and reviewed peptide shops directory help buyers evaluate vendor claims regardless of manufacturing tier.

How Are Specific Peptides Made? Compound Examples

The same Fmoc SPPS process manufactures every compound on Peptigrity's platform — but synthesis complexity varies enormously between a 4-amino-acid epitalon (3 coupling cycles, trivial yield) and a 31-amino-acid lipidated semaglutide (30+ cycles plus post-synthesis fatty acid attachment), which directly explains the price and purity differences buyers encounter across different compounds.

BPC-157 — 15 amino acids: Relatively short, straightforward synthesis requiring 14 coupling cycles. Contains multiple proline residues, which can slow coupling slightly, but no particularly difficult positions. High crude yield expected. The primary quality concern is methionine oxidation during cleavage and storage.

Semaglutide — 31 amino acids + C18 lipidation: Complex, multi-step synthesis. The peptide backbone is built by standard Fmoc SPPS, but the C18 fatty diacid side chain must be attached post-synthesis to lysine-26 through a specific glutamic acid spacer. This modification step adds significant complexity and cost. Novo Nordisk manufactures the FDA-approved product at multi-ton GMP scale — a production volume that has driven Fmoc building block costs down globally through economies of scale.

Epitalon — 4 amino acids (Ala-Glu-Asp-Gly): The simplest synthesis on Peptigrity's compound list. Only 3 coupling cycles. Very high crude yields. Solution-phase synthesis may be economically competitive for peptides this short.

CJC-1295 without DAC — 29 amino acids with 4 substitutions: Fmoc SPPS requiring 28 coupling cycles with non-standard amino acids at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, Leu). These require specialised Fmoc building blocks — commercially available but more expensive than standard amino acids.

GHK-Cu — 3 amino acids + copper chelation: The peptide itself (Gly-His-Lys) requires only 2 coupling cycles. The quality-critical step is the post-synthesis copper chelation — adding Cu²⁺ ions to form the biologically active metallopeptide at the correct 1:1 stoichiometry. An improperly metallated GHK-Cu may lack copper entirely (colourless instead of blue) or contain excess free copper. Mass spectrometry confirming the copper-bound molecular weight is the definitive quality check.

Frequently Asked Questions

Why are peptides built C-to-N instead of N-to-C like in biology?

In biological protein synthesis, ribosomes build polypeptides from N-terminus to C-terminus. In SPPS, the C-terminal amino acid is anchored first and the chain grows toward the N-terminus. This direction produces fewer side reactions — particularly less racemisation — because the incoming amino acid is activated at its carboxyl group and coupled to the free amine of the growing chain. The reverse direction would require activating the resin-bound chain's carboxyl at each step, which promotes racemisation and reduces product quality.

How long does it take to synthesise a peptide?

Each deprotection-coupling-wash cycle takes approximately 30–90 minutes. A 15-amino-acid peptide like BPC-157 requires ~14 cycles (7–12 hours of synthesis). A 30-amino-acid peptide requires ~29 cycles (1–2 days). Cleavage, HPLC purification, QC testing, and lyophilisation add another 1–3 days. Total turnaround from order to finished product is typically 1–3 weeks for research-grade peptides, including queue time at the synthesis facility.

What is a deletion peptide and why does it matter?

A deletion peptide is a sequence where one or more amino acids were skipped because coupling was incomplete — the unreacted amine continued in subsequent couplings, producing a peptide missing specific residues but otherwise similar to the target. Deletion peptides are the most problematic synthesis impurity because their chromatographic properties are very close to the target, making HPLC separation extremely difficult. Capping — acetylating unreacted amines after each coupling — prevents deletion peptides by terminating failed chains before they can continue growing.

Can longer peptides like semaglutide be made by SPPS alone?

Semaglutide's 31-amino-acid backbone is within standard SPPS capability. The complexity comes from the C18 fatty diacid side chain attached via a linker to Lys26 — a post-synthesis modification, not part of the SPPS cycle. For peptides exceeding approximately 50 amino acids, SPPS alone becomes impractical due to accumulated coupling errors. These are made by synthesising shorter fragments separately, then joining them via native chemical ligation. Very large peptides and proteins can alternatively be produced by recombinant expression in bacteria or yeast.

Why do research peptides have impurities even at ≥98% purity?

Even with optimised Fmoc SPPS, no coupling step achieves 100% efficiency. At 99.5% per step over 30 residues, ~14% of the crude product is incorrect. HPLC purification removes the majority, but the remaining 2–5% consists of closely related sequences — deletion peptides, oxidised variants, deamidated forms — that co-elute with the target because their chromatographic properties are nearly identical. This is a fundamental limitation of stepwise chemical synthesis, not a failure of any specific manufacturer, and it is why analytical HPLC data on a Certificate of Analysis is essential for confirming what you actually have.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.